Den europeiske union -
norsk -
EMA (European Medicines Agency)
xtandi
astellas pharma europe b.v. - enzalutamide - prostata neoplasmer - endokrin terapi - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
Norge -
norsk -
Statens legemiddelverk
bicalutamide teva 50 mg
teva sweden ab - bikalutamid - tablett, filmdrasjert - 50 mg
Norge -
norsk -
Statens legemiddelverk
bicalutamide teva 150 mg
teva sweden ab - bikalutamid - tablett, filmdrasjert - 150 mg
Norge -
norsk -
Statens legemiddelverk
casodex 150 mg
laboratoires juvisé pharmaceuticals - bikalutamid - tablett, filmdrasjert - 150 mg
Norge -
norsk -
Statens legemiddelverk
casodex 50 mg
laboratoires juvisé pharmaceuticals - bikalutamid - tablett, filmdrasjert - 50 mg
Norge -
norsk -
Statens legemiddelverk
casodex 50 mg
orifarm as - bikalutamid - tablett, filmdrasjert - 50 mg
Norge -
norsk -
Statens legemiddelverk
casodex 150 mg
orifarm as - bikalutamid - tablett, filmdrasjert - 150 mg
Norge -
norsk -
Statens legemiddelverk
casodex 150 mg
orifarm as - bikalutamid - tablett, filmdrasjert - 150 mg
Den europeiske union -
norsk -
EMA (European Medicines Agency)
erleada
janssen-cilag international nv - apalutamide - prostata neoplasmer - endokrin terapi - erleada er angitt:i voksne menn for behandling av metastatisk ikke kastrering motstandsdyktig mot prostatakreft (nmcrpc) som har høy risiko for å utvikle metastatisk sykdom. i voksne menn for behandling av metastatisk hormone-sensitive prostatakreft (mhspc) i kombinasjon med androgen mangel terapi (adt).
Den europeiske union -
norsk -
EMA (European Medicines Agency)
nubeqa
bayer ag - darolutamide - prostatic neoplasmer, kastrering-resistant - endokrin terapi - nubeqa is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmcrpc) who are at high risk of developing metastatic disease (see section 5. - metastatic hormone sensitive prostate cancer (mhspc) in combination with docetaxel and androgen deprivation therapy (see section 5.